Cargando…
A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design
BACKGROUND: No drug treatment to date has shown convincing clinical evidence of restoring cognitive function or preventing further decline after stroke. The ongoing ARTEMIDA study will evaluate the efficacy and safety of Actovegin for the symptomatic treatment of post-stroke cognitive impairment (PS...
Autores principales: | Guekht, Alla, Skoog, Ingmar, Korczyn, Amos D., Zakharov, Vladimir, Eeg, Martin, Vigonius, Ulf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919431/ https://www.ncbi.nlm.nih.gov/pubmed/24516413 http://dx.doi.org/10.1159/000357122 |
Ejemplares similares
-
ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment
por: Guekht, Alla, et al.
Publicado: (2017) -
Diabetes and the brain: issues and unmet needs
por: Bornstein, Natan M., et al.
Publicado: (2014) -
Actovegin in the management of patients after ischemic stroke: A systematic review
por: la Fleur, Philip, et al.
Publicado: (2022) -
Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report
por: Bordet, Régis, et al.
Publicado: (2017) -
Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial
por: Muresanu, Dafin F., et al.
Publicado: (2016)